Literature DB >> 9210512

Detection of HLA class I- and class II-specific antibodies by flow cytometry and PRA-STAT screening in renal transplant recipients.

A W Harmer1, A J Heads, R W Vaughn.   

Abstract

BACKGROUND: Screening for HLA-specific antibodies has been performed by complement-dependent lymphocytotoxicity for many years. In recent years, methods involving the use of flow cytometry or ELISA have been developed.
METHODS: This study has compared a flow cytometric screening technique for the detection of HLA class I- and class II-specific antibodies with a commercially available ELISA technique, PRA-STAT.
RESULTS: A significant correlation was found between the two methods for the detection of antibodies in patients after transplantation (P<0.001). Specificity analysis confirmed that the PRA-STAT technique detected both HLA class I- and class II-specific antibodies. Screening of serum samples from patients who experienced graft loss by cytotoxic, flow cytometric, and PRA-STAT techniques showed that there was a significant correlation between all three methods for the detection of antibody, but that the best correlation for the panel-reactive antibody level was that between the flow cytometric and PRA-STAT techniques (r=0.86). This was principally due to the detection of both HLA class I- and class II-specific antibodies by these methods, whereas cytotoxic screening detected only class I-specific antibodies.
CONCLUSIONS: These results suggest that PRA-STAT is a useful technique for the detection of both HLA class I- and class II-specific antibodies, rather than only class I-specific antibodies as previously described.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210512     DOI: 10.1097/00007890-199706270-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  HLA-antibody testing: the immune phagocytosis inhibition test is superior to the PRA-STAT and NIH lymphocytotoxic test with respect to specificity.

Authors:  B K Flesch; M Philipp; U Cassens; J Neppert
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 2.  Human leukocyte antigen antibodies for monitoring transplant patients.

Authors:  Junchao Cai; Paul I Terasaki
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

3.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.